Category Archives: Stem Cell Clinic


Stem Cell Clinic > Stem Cell Clinic

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

By Stem Cell Clinic

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Estradiol Gel, 0.06%. ANI’s Estradiol Gel, 0.06% is the generic version of the reference listed drug (RLD) EstroGel® Gel, 0.06%.

See the rest here:
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024

By Stem Cell Clinic

TEL AVIV, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment of patients with low-grade upper tract urothelial cancer (UTUC), will be presented at the 16th European Multidisciplinary Congress on Urological Cancers (EMUC 2024) taking place November 7 – 10, 2024, in Lisbon, Portugal.

Originally posted here:
ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

By Stem Cell Clinic

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.

Visit link:
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR…

By Stem Cell Clinic

VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is pleased to announce the presentation of its research on novel small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes at the 36th EORTC-NCI-AARC Symposium in Barcelona, Spain, on October 25, 2024.

More here:
Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR...

Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

By Stem Cell Clinic

CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th.

More here:
Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and…

By Stem Cell Clinic

WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that a subsequent analysis of the data from the pivotal study of its product candidate Anaphylm™ (epinephrine) Sublingual Film demonstrating comparable PK and PD data regardless of variable placement or intraoral movement will be presented at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, which is being held from October 24-28 in Boston, Massachusetts.

Read more here:
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and...

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

By Stem Cell Clinic

REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT.

Continue reading here:
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference

By Stem Cell Clinic

CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 30, 2024, at 9:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.

Read more:
Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference

→←